Patents by Inventor Gustav Gaudernack
Gustav Gaudernack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8614177Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.Type: GrantFiled: January 3, 2011Date of Patent: December 24, 2013Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
-
Publication number: 20130129760Abstract: A polypeptide comprising the sequence of SEQ. ID NO. 2, 3, 4, 7 or 8. The polypeptide may have the sequence of an immunogenic fragment thereof comprising at least eight amino acids, wherein the immunogenic fragment is not one of SEQ. ID NOS. 6 or 11 to 16. The polypeptide may have a sequence having at least 80% sequence identity to the aforementioned polypeptide or immunogenic fragment. The polypeptide is less than 100 amino acids in length and does not comprise the sequence of any of SEQ. ID NOS. 10, 46, 56, 57 or 59 to 62 and does not consist of the sequence of SEQ ID NO. 58. The polypeptide is useful in the treatment or prophylaxis of cancer.Type: ApplicationFiled: February 15, 2011Publication date: May 23, 2013Inventors: Gustav Gaudernack, Anne-Marie Rasmussen, Else Marit Inderberg Suso
-
Publication number: 20120269858Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: ApplicationFiled: May 31, 2012Publication date: October 25, 2012Applicant: GEMVAX ASInventors: Gustav GAUDERNACK, Stein SÆBØE-LARSSEN, Mona MØLLER, Jon Amund ERIKSEN
-
Patent number: 8193326Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: GrantFiled: March 5, 2008Date of Patent: June 5, 2012Assignee: GemVax ASInventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
-
Publication number: 20110105721Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the inventions are also described.Type: ApplicationFiled: January 3, 2011Publication date: May 5, 2011Applicant: GEMVAX ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
-
Patent number: 7863244Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: GrantFiled: August 3, 2006Date of Patent: January 4, 2011Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
-
Patent number: 7794723Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.Type: GrantFiled: January 17, 2006Date of Patent: September 14, 2010Assignee: GemVax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal, Stein Sæbøe-Larsen
-
Publication number: 20080187551Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: ApplicationFiled: March 5, 2008Publication date: August 7, 2008Applicant: GEM VAX ASInventors: Gustav Gaudernack, Stein Saeboe-Larssen, Mona Moller, Jon Amund Eriksen
-
Patent number: 7375117Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognizing and destroying tumor cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: GrantFiled: March 29, 2006Date of Patent: May 20, 2008Assignee: GemVax ASInventors: Gustav Gaudernack, Stein Sæøe-Larssen, Mona Møller, Jon Amund Eriksen
-
Patent number: 7192927Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: GrantFiled: February 12, 2004Date of Patent: March 20, 2007Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller, Marianne Klemp Gjertsen, Ingvil Saeterdal
-
Publication number: 20070004632Abstract: Peptides from cancer related protein products of frameshift mutated genes which eliciting T cellular immunity for use in cancer vaccines and compositions for anticancer treatment.Type: ApplicationFiled: August 3, 2006Publication date: January 4, 2007Applicant: GEMVAX ASInventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal
-
Publication number: 20060194731Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: ApplicationFiled: March 29, 2006Publication date: August 31, 2006Applicant: GemVax AsInventors: Gustav Gaudernack, Stein Saeboe-Larssen, Mona Moller, Jon Eriksen
-
Patent number: 7078416Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: GrantFiled: December 18, 2001Date of Patent: July 18, 2006Assignee: GemVax ASInventors: Gustav Gaudernack, Stein Sæbøe-Larssen, Mona Møller, Jon Amund Eriksen
-
Publication number: 20060106196Abstract: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and destroying tumor cells in a mammal. More specifically, a telomerase protein or peptide for use in a method of treatment or prophylaxis of cancer is provided. In a preferred embodiment, the method comprises generating a T cell response against telomerase.Type: ApplicationFiled: January 17, 2006Publication date: May 18, 2006Applicant: GemVax ASInventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal, Stein Saeboe-Larsen
-
Publication number: 20050074849Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: ApplicationFiled: February 12, 2004Publication date: April 7, 2005Applicant: GEMVAX ASInventors: Gustav Gaudernack, Jon Eriksen, Mona Moller, Marianne Gjertsen, Ingvil Saeterdal
-
Patent number: 6861057Abstract: Frameshift Mutants ?-Amyloid precursor peptides and mutant ubiquitin-B associated with Alzheimer's disease and Down syndrome eliciting T cellular immunity for use in compositions for the treatment and/or prophylaxis of Alzheimer's disease and/or Down syndrome.Type: GrantFiled: April 30, 1999Date of Patent: March 1, 2005Assignee: GemVax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller
-
Publication number: 20040235175Abstract: The present invention relates to a method of inserting RNA into cells. In this method, cells are transfected with RNA using electroporation in order to achieve high transfection efficiency. The method is useful, inter alia, in providing cells to be used in cell-based therapies, e.g. in preparing cells useful as anti-cancer vaccines. Preferably, the RNA has a 5′ cap and a 3′ poly (A) tail.Type: ApplicationFiled: November 4, 2003Publication date: November 25, 2004Inventors: Gustav Gaudernack, Stein Saeboe-Larssen
-
Patent number: 6759046Abstract: Isolated peptides that are fragments of protein products arising from frameshift mutations in genes associated with cancer are disclosed. The isolated peptides of the invention are capable of eliciting T cell immunity against cells harboring genes with such frameshift mutations. Cancer vaccines and therapeutically effective compositions containing the peptides of the invention are also described.Type: GrantFiled: June 4, 2001Date of Patent: July 6, 2004Assignee: Gemvax ASInventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Møller, Marianne Klemp Gjertsen, Ingvil Sæterdal
-
Publication number: 20040072759Abstract: The present invention relates to polypeptides, and nucleic acids DNA encoding these polypeptides, capable of eliciting an immune reaction against cancer, methods for generating T lymphocytes capable of recognising and destroying tumour cells, and pharmaceutical compositions for the treatment, prophylaxis or diagnosis of cancer.Type: ApplicationFiled: June 19, 2003Publication date: April 15, 2004Inventors: Gustav Gaudernack, Stein Saeboe-Larssen, Mona Moller, Jon Amund Eriksen
-
Publication number: 20030171266Abstract: Frameshift Mutants &bgr;-Amyloid precursor peptides and mutant ubiquitin-B associated with Alzheimer's disease and Down syndrome eliciting T cellular immunity for use in compositions for the treatment and/or prophylaxis of Alzheimer's disease and/or Down syndrome.Type: ApplicationFiled: May 25, 2001Publication date: September 11, 2003Inventors: Gustav Gaudernack, Jon Amund Eriksen, Mona Moller